B7-H3 Antibody (D-8): sc-398444
- B7-H3 Antibody (D-8) is a mouse monoclonal IgG2b κ, cited in 1 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 83-108 near the N-terminus of B7-H3 of human origin
- recommended for detection of B7-H3 of mouse, rat and human origin by WB, IP, IF and ELISA; also reactive with additional species, including and canine and bovine
- m-IgG2b BP-HRP and m-IgGκ BP-HRP are the preferred secondary detection reagents for B7-H3 Antibody (D-8) for WB applications. These reagents are now offered in bundles with B7-H3 Antibody (D-8) (see ordering information below).
QUICK LINKS
SEE ALSO...
B7-H3 Antibody (D-8) is a mouse monoclonal IgG2b antibody that detects B7-H3 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). B7-H3, also known as B7-homolog 3 or B7RP-2, is a member of the B7 Immunoglobulin superfamily and plays a crucial role in regulating T cell activation and immune responses. B7-H3 is predominantly expressed on non-lymphoid tissues, where B7-H3 engages with a putative receptor on activated T cells distinct from other well-known costimulatory molecules like CD28 and PD-1. B7-H3′s unique interactions with T cells promote proliferation of both CD4+ and CD8+ T cells and suggest involvement in enhancing Th1 and cytotoxic T cell responses, which may contribute to potential antitumor activity. B7-H3′s ability to modulate cell-mediated immune responses against cancer positions B7-H3 as a promising candidate for therapeutic applications, making anti-B7-H3 antibody (D-8) an invaluable tool for researchers exploring immune regulation and cancer immunotherapy.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
B7-H3 Antibody (D-8) References:
- B7-H3 role in the immune landscape of cancer. | Castellanos, JR., et al. 2017. Am J Clin Exp Immunol. 6: 66-75. PMID: 28695059
- Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. | Liu, C., et al. 2022. Cancer Immunol Immunother. 71: 1549-1567. PMID: 34739560
- Targeting B7‑H3 through EZH2 inhibition in MYC‑positive Group 3 medulloblastoma. | Shishido, K., et al. 2023. Oncol Rep. 49: PMID: 37114557
- B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer. | Li, S., et al. 2023. Cell Death Discov. 9: 147. PMID: 37149721
- Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1/mTOR/VEGFA pathway. | Wu, R., et al. 2023. Cell Signal. 109: 110737. PMID: 37263461
- ITC-6102RO, a novel B7-H3 antibody-drug conjugate, exhibits potent therapeutic effects against B7-H3 expressing solid tumors. | Shin, SH., et al. 2023. Cancer Cell Int. 23: 172. PMID: 37596639
- B7-H3 regulates anti-tumor immunity and promotes tumor development in colorectal cancer. | Zhang, H., et al. 2024. Biochim Biophys Acta Rev Cancer. 1879: 189031. PMID: 38036107
- High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors in triple-negative breast cancer. | Mei, J., et al. 2024. NPJ Breast Cancer. 10: 11. PMID: 38280882
- B7-H3 Expression in Breast Cancer and Brain Metastasis. | Joshi, V., et al. 2024. Int J Mol Sci. 25: PMID: 38612786
- A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer. | Zhou, ZZ., et al. 2024. Cancer Res. 84: 3848-3863. PMID: 39186778
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
B7-H3 Antibody (D-8) | sc-398444 | 200 µg/ml | $322.00 | |||
B7-H3 Antibody (D-8): m-IgGκ BP-HRP Bundle | sc-536061 | 200 µg Ab; 40 µg BP | $361.00 | |||
B7-H3 Antibody (D-8): m-IgG2b BP-HRP Bundle | sc-549508 | 200 µg Ab; 10 µg BP | $361.00 | |||
B7-H3 (D-8) Neutralizing Peptide | sc-398444 P | 100 µg/0.5 ml | $69.00 |